Chiasma Inc. to Present at the UBS Global Life Sciences Conference
Published: Sep 14, 2011
NEW YORK and JERUSALEM, Sept. 14, 2011 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that Fredric Price, Chiasma's Chairman & CEO, will present an overview of the Company at the UBS Global Life Sciences Conference at the Grand Hyatt, New York, New York, on Monday, September 19, 2011 at 1:30 PM.
Chiasma's investigational new drug Octreolin is an oral form of octreotide acetate being developed first for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone. The Company successfully completed 4 clinical studies with Octreolin in healthy volunteers, having established a pharmacokinetics profile similar to that of subcutaneously injected octreotide acetate. In addition, Octreolin demonstrated the ability to reduce growth hormone. No serious adverse safety events were reported in any of the studies. A trial in patients will commence in October 2011. Chiasma intends to file an NDA using the 505(b)(2) regulatory pathway in the US and its EMA equivalent, the Hybrid Application in Europe.
Octreolin is also being developed as a chronic treatment for patients with Portal Hypertension (PHT); a Phase 2 proof of concept trial for this new orphan indication (no drugs are approved for PHT in the US) was initiated in September 2011. The Company has a pipeline of products that are currently in preclinical development including one in renal disease that will enter the clinic in mid-2012.
Chiasma develops new drug products based on its proprietary Transient Permeability Enhancer (TPE) technology, which enables oral delivery of macromolecules (up-to 20 kDa) and poorly-absorbed small molecules into the portal system and then to the systemic circulation. The TPE technology not only enables their being converted from injectable to oral, but importantly can result in the development of new indications.
Chiasma is a Delaware corporation with a 100% owned Israeli subsidiary. It is backed by MPM Capital, ARCH Venture Partners, F-2 Ventures and 7 Med Health Ventures.
Additional information can be found at: www.ChiasmaPharma.com.
This press release contains forward-looking statements about the business, goals and prospects of Chiasma, Inc., including, without limitation, statements about the development of drugs in the TPE system. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. Chiasma is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
SOURCE Chiasma, Inc.